Sun Pharma Monday said it will acquire Japan-based Pola Pharma for around USD 1 million to strengthen its presence in dermatology segment across the globe. The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharmaceutical Industries said in a statement. Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations. "This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future," Sun Pharma Executive Vice-President Kirti Ganorkar said. Sun Pharma Japan Country Head .
from Companies https://ift.tt/2KzVOUL
via IFTTT
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
While sales to original equipment manufacturers declined 16.3% year on year in FY20, the replacement market sales declined by a modest 2.6% ...
-
India's passenger vehicle sales are expected to grow between 3-5 percent in the current fiscal year, after expanding at the slowest pace...
-
The earnings momentum has been quite resilient and the policy momentum quite focused towards improving the infrastructure and attractiveness...
No comments:
Post a Comment